Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Pharma
Outlook stock plummets as FDA again snubs wet AMD drug
For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.
Angus Liu
Aug 28, 2025 10:55am
FDA denies Regeneron's bid for dosage flexibility on Eylea
Apr 21, 2025 8:45am
JPM25: Regeneron has few answers for declining sales of Eylea HD
Jan 14, 2025 10:25am
Asian patients with PCV show improvement with Roche's Vabysmo
Nov 22, 2024 7:00am
EyePoint's Duravyu bounces back with promising DME data
Oct 28, 2024 1:11pm
Astellas pulls application for Izervay after talks with CHMP
Oct 28, 2024 11:07am
